Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

Author： Johnson Peter   Geldart Thomas   Fumoleau Pierre   Pinel Marie-Claire   Nguyen Laurent   Judson Ian  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.24, Iss.3, 2006-05, pp. : 223-231

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

By Chen Eric   Batist Gerald   Siu Lillian   Bangash Naeema   Maclean Martha   McIntosh Lynn   Miller Wilson   Oza Amit   Lathia Chetan   Petrenciuc Oana   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 455-465

Springer Publishing Company

Access to resources Recommend Favorite

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

By Gelmon K.   Hirte H.   Fisher B.   Walsh W.   Ptaszynski M.   Hamilton M.   Onetto N.   Eisenhauer E.  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 263-275

Springer Publishing Company

Access to resources Recommend Favorite

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

By Hilgers Werner   Faivre Sandrine   Chieze Stéphanie   Alexandre Jérôme   Lokiec François   Goldwasser François   Raymond Eric   Kahatt Carmen   Taamma Abdelkrim   Weems Garry   MacDonald John   Misset Jean-Louis   Cvitkovic Esteban  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 311-319

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

By Ramanathan Ramesh  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1591-1596

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

By Royce Melanie E.   Rowinsky Eric K.   Hoff Paulo M.   Coyle John   DeJager Robert   Pazdur Richard   Saltz Leonard B.  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite